Linked Life Data

17698345

Source:http://linkedlifedata.com/resource/pubmed/id/17698345

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
2007-10-15
pubmed:abstractText
Aromatase inhibitors and inactivators (AIs) have been/are being widely investigated as an alternative to tamoxifen in the treatment of postmenopausal breast cancer patients. In this paper we have reviewed data from phase III studies to define the role of AIs versus tamoxifen as first-line therapy in patients with metastatic breast cancer, as primary therapy for not operable or early breast cancers not suitable for conservative surgery and as adjuvant treatment for women with early breast cancer. An effort has been performed to evaluate whether specific recommendations were needed for older postmenopausal patients. AIs play a key role in the treatment of advanced breast cancer and represent the agent of choice in patients who are candidates to neoadjuvant hormone-therapy. Longer follow-up of already published trials and additional data coming from ongoing studies will better define when and how to use AIs in the adjuvant setting.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2270-8
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
pubmed:affiliation
Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Tuscany Cancer Institute, Piazza dell'Ospedale, 59100 Prato, Italy. lbiganzoli@usl4.toscana.it
pubmed:publicationType
Journal Article, Review